We had already confirmed that treatment with LPS stimulated the NF‐κB pathway in MDSCs,14 and it was reported that oxaliplatin treatment affected NF‐κB signaling in a cancer cell line.27 In the present study, we found that oxaliplatin treatment blocked NF‐κB activation in LPS‐stimulated MDSCs. Here, NFKB1 is linked to cancer.